UY35301A - Formulación en dispersión sólida de un compuesto antiviral - Google Patents

Formulación en dispersión sólida de un compuesto antiviral

Info

Publication number
UY35301A
UY35301A UY35301A UY35301A UY35301A UY 35301 A UY35301 A UY 35301A UY 35301 A UY35301 A UY 35301A UY 35301 A UY35301 A UY 35301A UY 35301 A UY35301 A UY 35301A
Authority
UY
Uruguay
Prior art keywords
compound
formulation
solid dispersion
antiviral compound
disclosed
Prior art date
Application number
UY35301A
Other languages
English (en)
Inventor
Zia Vahid
Oliyai Reza
Mogalian Erik
Stefanidis Dimitrios
Gorman Eric
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of UY35301A publication Critical patent/UY35301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Se divulgan dispersiones sólidas que comprenden un compuesto que tiene la fórmula: caracterizadas porque el compuesto es dispersado dentro de una matriz polimérica formada por un polímero aceptable desde el punto de vista farmacéutico, y caracteriza das además porque el compuesto es sustancialmente amorfo. También, se divulgan las composiciones farmacéuticas que comprenden el compuesto así como los métodos de uso para el compuesto.
UY35301A 2013-08-27 2014-01-31 Formulación en dispersión sólida de un compuesto antiviral UY35301A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361870703P 2013-08-27 2013-08-27

Publications (1)

Publication Number Publication Date
UY35301A true UY35301A (es) 2015-03-27

Family

ID=50097890

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35301A UY35301A (es) 2013-08-27 2014-01-31 Formulación en dispersión sólida de un compuesto antiviral

Country Status (5)

Country Link
US (1) US20150064252A1 (es)
AR (1) AR095132A1 (es)
TW (1) TW201511780A (es)
UY (1) UY35301A (es)
WO (1) WO2015030854A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083711A1 (es) 2010-11-17 2013-03-20 Gilead Sciences Inc Compuestos heterociclicos utiles en el tratamiento de la hepatitis c
RS54207B1 (en) 2011-11-16 2015-12-31 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
CN107343877A (zh) * 2016-05-06 2017-11-14 常州爱诺新睿医药技术有限公司 一种无定型维帕他维的固体分散体及其制备方法
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
PT3541807T (pt) 2016-11-16 2021-12-09 H Lundbeck As Uma forma cristalina de um inibidor de magl
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
PT1469833T (pt) 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
CN100528875C (zh) 2005-02-18 2009-08-19 美德（江西）生物科技有限公司 无结晶型态的印地普隆及其制备方法
EP2100606A4 (en) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd COATED PREPARATION OF A FILM HAVING IMPROVED STABILITY
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
AR083711A1 (es) * 2010-11-17 2013-03-20 Gilead Sciences Inc Compuestos heterociclicos utiles en el tratamiento de la hepatitis c
RS54207B1 (en) 2011-11-16 2015-12-31 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
TW201511780A (zh) 2015-04-01
AR095132A1 (es) 2015-09-30
WO2015030854A1 (en) 2015-03-05
US20150064252A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
UY35301A (es) Formulación en dispersión sólida de un compuesto antiviral
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
ECSP16000724A (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
UY37098A (es) Moduladores de ror-gamma
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CL2018000786A1 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
PH12016500793A1 (en) Turmeric extract containing soft pastilles
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CR20160016A (es) Pirazolpiridinas sustituidas
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211029